mirvetuximab
immunogen
['4147', 'mirvetuximab', 'immunogen']
poster presentations are in session at #asco22! swing by posters 450 and 391 to review the latest safety and efficacy data from our #mirvetuximab soravtansine program and stop by booth 24147 to discuss the data with our msls. 
We exist to interrupt the progress of cancer so cancer can't interrupt the lives of our patients. #TargetABetterNow

Policy: https://t.co/MLtPQiuFPo